Protocol
Multi-domain diet and lifestyle program with supplements (8 weeks, as studied)
One pilot randomized trial in 43 healthy men aged 50 to 72 tested an 8-week program of diet, sleep, exercise and relaxation guidance plus a probiotic and a phytonutrient powder, against no intervention.
Grade C: human trials exist, but they are small, mixed or not yet repeated. This is not a finding that it does not work. How to read a grade →
Compare this record with another, side by side →
How this letter has changedLatest: October 2026 · Corrected.
The description said one trial reported reversal of an epigenetic clock A test that estimates biological age from chemical marks on DNA (DNA methylation).. The trial (Fitzgerald et al., Aging, 2021; PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 33844651) randomized 43 men aged 50 to 72 to a program that included two supplements from the funder; the within-group change was not significant (p=0.066) and only the between-group difference was (p=0.018), so reversal overstated it. The record now names the clock (the 2013 Horvath clock, in saliva), the population, the supplements, the two published corrections (PMID 35907207, PMID 38488762) and the authors' uncontrolled case series in six women (PMID 36947707), which is not a replication The same finding reproduced by a separate research group. A result seen once can be chance or bias; a replicated one is harder to explain away.. The track field, which described a FINGER-style cognitive battery the trial never measured, now follows the trial's own endpoint The outcome a trial measures to decide whether the treatment worked, such as heart attacks, blood pressure or a symptom score.. In the pattern applied to other protocols the name states what was studied. C unchanged. Applied the written grade definition under the editor's standing instruction of October 2026 (Arnold Sandlow, D.C.).PMID 33844651 PMID 35907207 PMID 36947707 PMID 38488762
Funding stated in the evidence. The single pilot trial, Fitzgerald 2021 (PMID 33844651), was supported by an unrestricted grant from the company that makes the two supplements in the program, and its two lead authors use the program in practice, hold a related patent application and earn from its educational products. Letter unchanged.PMID 33844651
Every change to a letter on this site is dated and published. The full evidence log →
This program combined diet, exercise, sleep and stress changes with two supplements for 8 weeks. One small study included 43 men aged 50 to 72. In the men on the program, a saliva test meant to estimate body age came out lower than in men who made no changes. The change within the program group alone was not clear. Part of the gap came from the other group's estimated age going up.
One pilot randomized trial in 43 healthy men aged 50 to 72 tested an 8-week program of diet, sleep, exercise and relaxation guidance plus a probiotic and a phytonutrient powder, against no intervention. Saliva DNA methylation age on the 2013 Horvath clock was 3.23 years lower than in controls (p=0.018); the within-group fall of 1.96 years was not significant (p=0.066), so the result is a between-group difference, not a demonstrated reversal. The trial was funded by the maker of the two supplements, and the paper has two published corrections. No randomized trial has repeated the program; the authors' follow-up in women was an uncontrolled case series of six. Pilot-sized, single trial, surrogate endpoint A lab value or measurement used in place of the outcome that matters, such as LDL cholesterol standing in for heart attacks. Moving a surrogate does not always move the outcome.: C.
Why this gradeGrade C, small or unreplicated trials. The reasoning, and what the grade does not cover.
Grade C, resting on one small pilot randomized trial of an 8-week diet and lifestyle program that also included two supplements, reporting a lower saliva DNA methylation age than no-intervention controls in 43 men aged 50 to 72 (Fitzgerald et al., 2021; PMID 33844651). The within-group change was not significant, the control group's clock age rose in 8 weeks, and the paper carries two published corrections (PMID 35907207, PMID 38488762). It has not been independently replicated: the authors' own follow-up in women (PMID 36947707) was an uncontrolled case series. Other randomized trials that moved epigenetic clocks tested different interventions in different populations and cannot replicate this one. The endpoint is a first-generation clock in saliva, a surrogate whose link to clinical outcomes is unsettled. The trial was supported by the maker of the two supplements in the program, and the lead authors use the program commercially.
WHAT THIS GRADE DOES NOT COVERbiological aging as a clinical outcome, lifespan, women (none were randomized), lifestyle change without the supplements, or any single component of the program tested on its own.
A grade describes the human evidence for a named use. It is not advice, and it is not a judgment on any individual prescription. How the letters are decided →
The evidence, in fullFour papers, each linked to its PubMed record.
Fitzgerald et al. (Aging, 2021; PMID 33844651): pilot randomized controlled trial People are assigned to the treatment or a comparison by chance, so the groups differ only in what they received. It is the design that can show cause and effect., 43 healthy men aged 50 to 72, 8-week program of diet, sleep, exercise and relaxation guidance with supplemental probiotics and phytonutrients, against no intervention; saliva Horvath 2013 DNA methylation age 3.23 years lower than controls (p=0.018), within-group change 1.96 years, not significant (p=0.066); serum 5-methyltetrahydrofolate up and triglycerides down. Two corrections have been published (Aging, 2022; PMID 35907207; Aging, 2024; PMID 38488762). Fitzgerald et al. (Aging, 2023; PMID 36947707): the same program in six women, an uncontrolled case series, so not a replication. The endpoint is an epigenetic clock, a surrogate whose relationship to clinical outcomes is unsettled. Grade C reflects small single-trial human data. Funding: the paper states the trial was supported by an unrestricted grant from the company that makes the two supplements in the intervention arm, and that the two lead authors use the program in clinical practice, are named on a related patent application and earn from educational products associated with it, while stating they were not involved in day-to-day conduct, sample collection or analysis.
The trial's endpoint was a saliva DNA methylation clock at baseline and 8 weeks; no cognitive or cardiometabolic composite was measured. Readers following a clock should use the same clock and tissue at both points. Adherence to each component (diet, sleep schedule, exercise, relaxation, supplements) in a diary is the process measure, since the trial did not test them apart.
Evidence notes: randomized trial, pilot study, not independently replicated
Endpoint graded: DNA methylation age, an epigenetic clock (surrogate)
Last reviewed: July 2026
Educational use only · Not medical advice · EBL grades published human evidence and does not recommend treatment. Stopping a prescription is a decision for your physician.
Evidence Based Longevity, Inc. is owner-operated and edited by Arnold Sandlow, D.C., a California-licensed chiropractor. Evidence Based Longevity publishes in English only · Machine translations are not produced or reviewed by EBL for accuracy
© Evidence Based Longevity, Inc.. All rights reserved
These statements have not been evaluated by the Food and Drug Administration. Any grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.
Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →